The impacts of the COVID-19 pandemic on the life science sector are being seen and felt worldwide, with various factors influencing key global markets. This BioForum will provide attendees with insight into the impact on the US healthtech market, with particular focus on factors that Australian businesses need to consider in relation to US market access.
US and Australian-based experts will provide an overview of the current landscape affecting medtech and biotech sectors in the US, delivering insights into the emerging risks to Australian businesses wanting to enter the US market, including how best to approach US business in the current climate. Impact to trade and global supply chains will also be considered, together with a review of current and emerging investment opportunities, and funding challenges that lie ahead.
Target Audience: Australian healthtech executives (spanning medtech, biotech, pharma and digital health) and relevant industry service providers, whether currently engaged in business in the US or with strategic intent to expand into the US market.
Date (AEST): Thursday 25 June 2020 Time (AEST): 8:00am to 9:00am – Presentations and Q&A Discussion Date (EDT): Wednesday 24 June 2020 Time (EDT): 6:00pm to 7:00pm – Presentations and Q&A Discussion Format: This event will be delivered on a virtual platform – you will receive a link to join via confirmation email prior to the event. Tickets: Members $35, Non Members $45 We appreciate your ongoing support for the delivery of BioMelbourne Network events.
Laurie Halloran, President and Chief Executive Officer, Halloran Consulting (Boston, US)
Bede-Julian (BJ) Hampton, Investment Director for Healthcare, Resources and Energy, Australian Trade and Investment Commission (Austrade) (New York, US) Dr Chris Nave, Managing Director, Brandon Capital Partners (AUS) Raymond (Ray) Knox, Chief Manufacturing Officer, Lyndra Therapeutics (Boston, US)
Full refund given up to 3 days prior to the event.
No refunds within 3 days of the event.
Laurie Halloran, President and Chief Executive Officer, Halloran Consulting (Boston, US)
Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the cost. Since its humble beginnings, Halloran has grown into a successful consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do.
Laurie has been named 2018 Women’s Business Enterprise Star by the Women's Business Enterprise National Council (WBENC) and has won a 2017 Enterprising Women of the Year Award from Enterprising Women Magazine. Halloran Consulting Group was also named an Inc. 5000 Fastest Growing Company for the past three years in a row. In 2015, Laurie was honored by the Boston Business Journal as a Woman of Influence, in 2010 was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice, and in 2009, she was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals.
Laurie lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program. She has previously taught at George Washington University and Harvard University. Laurie earned a Bachelor of Science in nursing from Russell Sage College and a Master of Science in Management from Lesley University. She is also a Prosci Certified Change Practitioner.
Bede-Julian (BJ) Hampton, Investment Director for Healthcare, Resources and Energy, Australian Trade and Investment Commission (Austrade) (New York, US)
Austrade is the Australian Government’s international trade promotion and investment attraction agency. Austrade provides in-market insights, promotes Australian capability, and facilitates connections through its extensive global network. The North American market remains a key source of investment into the Australian biotech sector. Austrade has healthcare sector representation in Houston, New York, Boston, Chicago, Washington DC and Toronto.
While keeping tabs on trade opportunities for Australian companies in the US, BJ Hampton and his regional colleagues are pursuing catalytic foreign direct investment in Australian biotech and biomanufacturing to reinforce Australia’s capability in clinical research and global export potential.
BJ has multi-industry experience in Australian and US healthcare, mining and energy sectors. Most recently he delivered growth strategy and business intelligence for a fast-growing point-of-care digital marketing startup serving the most demanding Top 20 pharma clients.
BJ earned an MBA from the University of Queensland, Graduate Diploma in Management from the University of Otago, and Bachelor of Jurisprudence (Global Governance, Public Law) from Bond University.
Dr Chris Nave, Managing Director, Brandon Capital Partners (AUS)
Chris is a Founding Partner and Managing Director of Brandon Capital Partners; and Chief Executive Officer of the Medical Research Commercialisation Fund.
Brandon Capital was established in 2007 with $30M in investment capital. The firm now has over $800M in funds under management and a portfolio of over 30 innovative biotech and medtech companies.
Previous roles both locally and internationally in the pharmaceutical industry, technology transfer and biotechnology industries have seen Chris involved directly in the management, fundraising, technology development, of various companies in the life sciences industry.
In October 2014, Chris was awarded the AusBiotech Johnson & Johnson Industry Leadership Award, for his role in supporting the growth of the Australian biotechnology industry and for the internship and mentoring programs that he established to help develop the next generation of leaders.
Chris is currently a director of OccuRx Pty Ltd, Osprey Medical Inc., PolyActiva Pty Ltd, Global Kinetics Corporation, EBR Systems Inc, QueOncology Pty Ltd, Azura Ophthalmics, Certa Therapeutics and Cardiora Pty Ltd. Chris was Chairperson of Fibrotech Therapeutics at the time of its successful sale to Shire and a Director of Spinifex Pharmaceuticals at the time of its sale to Novartis. Chris has successfully taken portfolio companies public on both the ASX and NASDAQ and has been involved in taking medical technologies from concept through to regulatory approval, market launch and global sales.
Raymond (Ray) Knox, Chief Manufacturing Officer, Lyndra Therapeutics (Boston, US)
Ray is the Chief Manufacturing Officer at Lyndra Therapeutics and is responsible for all manufacturing operations. Ray has significant experience and success across multiple sectors of the Medical Device industry and demonstrated leadership in functions critical to successfully bringing these highly regulated products to market.
Ray has been in the medical device and combination therapy world since qualifying as a Mechanical Engineer from University College Dublin. Ray spent the majority of his early career working with large multi-national organizations, including Becton Dickinson, USCI, Medtronic and Boston Scientific in manufacturing, product development, program management and Quality Assurance roles. And since 2003 has focused on combination drug-device or device drug product.
After leaving Boston Scientific in 2010 Ray has focused on scaling manufacturing to support start-up companies and in bringing those technologies to commercial launch. In his current role as Chief Manufacturing Officer at Lyndra Therapeutics, he is responsible for scaling unique technologies more typical in non-pharmaceutical industry, in the development of an ultra long lasting oral dosage form.
Elane’s career spans academic, executive management, director, and management consulting roles, almost exclusively focused on life sciences and medical technologies. Her experience includes private sector (SME & multinational companies), universities, CRCs, and Federal and State government committees.
She has more than 20 years’ experience advising and assisting start-up and early stage companies, university spin-outs and research teams with strategic decision-making and risk management, governance, as well as strategic guidance for capital raising and commercialisation. Much of this activity has involved the intersection between the research sector and business.
Elane is a Commercialisation Adviser with the Australian Government’s Accelerating Commercialisation (AC) program. In this role she has assisted more than 150 companies, university/research institute spin-outs and research teams to develop and refine their growth strategies. Many have received grants from AC and private investors, leading to their valuable participation in the Australian economy.
Elane obtained her BSc (Hons), PhD & Grad Dip Mktg at Monash University, and completed post-doctoral studies at McMaster University, Hamilton, Ontario, Canada and University of Virginia, Charlottesville, Virginia, USA. In 2017 she was awarded the Distinguished Alumni Award by Monash’s Faculty of Science.
She continues to use her knowledge and skills to assist start-up/early stage companies and research based organisations to develop novel, value-add products in life sciences, healthcare and related sectors.